Taxane

Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.

Datopotamab deruxtecan (Dato-DXd) is poised to become a standard treatment for metastatic hormone receptor-positive, HER2-negative breast cancer after prior systemic therapy.

A phase III trial of ARX788 showed a significantly longer median progression-free survival (PFS) of 11.3 months compared to 8.2 months with lapatinib plus capecitabine (LC) in HER2-positive advanced breast cancer patients.

The FDA has approved Enhertu for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after endocrine therapy progression.

A groundbreaking clinical trial demonstrates that combining NOS inhibitor L-NMMA with taxane therapy shows significant clinical benefit in metaplastic breast cancer (MpBC) patients, with a 46% clinical benefit rate. The study reveals that NOS inhibition works synergistically with PI3K inhibitors and taxane chemotherapy by reversing epithelial-mesenchymal transition (EMT) and targeting cancer stem cells, potentially offering a new therapeutic strategy for this aggressive breast cancer subtype.